Dianthus therapeutics highlights recent business achievements and reports q1 financial results

Completed enrollment in phase 2 magic trial of dnth103 in generalized myasthenia gravis (gmg) top-line magic results anticipated in september 2025 to be the first of three catalysts for the dnth103 neuromuscular franchise by ye'26 phase 3 captivate trial of dnth103 in chronic inflammatory demyelinating polyneuropathy (cidp) ongoing; interim responder analysis anticipated in 2h'26 phase 2 momentum trial of dnth103 in multifocal motor neuropathy (mmn) ongoing; top-line results anticipated in 2h'26 $331.5 million of cash provides runway into 2h'27 new york and waltham, mass., may 12, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending march 31, 2025, and provided an update on recent business achievements.
DNTH Ratings Summary
DNTH Quant Ranking